Siratiazem

CAS: 138778-28-6

Ref. 3D-FS170126

Informação sobre produto

• Nome: Siratiazem
• Sinónimos: Siratiazem [INN], (+)-(2S,3S)-2,3-Dihydro-3-hydroxy-5-(2-(isopropylmethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate (ester), Unii-Chj1X6Ag9F, 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methyl(1-methylethyl)amino)ethyl)-, cis-(+)-, (2S,3S)-2-(4-methoxyphenyl)-5-{2-[methyl(propan-2-yl)amino]ethyl}-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate

Descrição

Siratiazem is a calcium-channel blocker that is used for the treatment of cardiac arrhythmia and hypertension, as well as for the prevention of congestive heart failure. Siratiazem is a prodrug that is converted to its active form by hydrolysis in the liver. It binds to the L-type calcium channels in cardiac muscle cells, thereby blocking calcium influx and decreasing the excitability of these cells. This drug has been shown to be effective in phase 1 clinical trials, with no major adverse effects. Siratiazem can cause symptoms such as nausea, vomiting, diarrhea, or constipation and may also have effects on insulin resistance and ventricular dysfunction.

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 442.57 g/mol
• Fórmula: C₂₄H₃₀N₂O₄S
• Pureza: Min. 95%